Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2021 Annual Meeting of Stockholders (the "Annual Meeting") of Alnylam Pharmaceuticals, Inc. (the "Company") was held on May 18, 2021. As of March 29, 2021, the record date for the Annual Meeting, 117,320,127 shares of the Company's common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

1. The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2024 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows:





                                            Votes
                             Votes For     Against    Abstentions   Broker Non-Votes

Dennis A. Ausiello, M.D. 100,520,054 1,188,272 6,497 3,978,315 Olivier Brandicourt, M.D. 99,910,483 1,793,713 10,627 3,978,315 Marsha H. Fanucci

           95,079,032    6,627,461      8,330         3,978,315
David E.I. Pyott            95,819,592    5,887,341      7,890         3,978,315


The terms of office of the following directors continued after the Annual
Meeting:

Michael W. Bonney

Margaret A. Hamburg, M.D.

John M. Maraganore, Ph.D.

Steven M. Paul, M.D.

Colleen F. Reitan

Amy W. Schulman

Phillip A. Sharp, Ph.D.

2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting results were as follows:





Votes For    Votes Against   Abstentions   Broker Non-Votes
81,382,437    20,146,079       186,307        3,978,315

--------------------------------------------------------------------------------

3. The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2021. The voting results were as follows:





 Votes For    Votes Against   Abstentions   Broker Non-Votes
105,476,472      206,905         9,761             0

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:





104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses